BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Nov 6, 2025
First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end
Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions
Read more at globenewswire.com
